Companies: 10,795·Total market cap: $144.5T
MetaVia Inc.

MetaVia Inc.

MTVANASDAQHealthcare● Active
$1.72
$-0.51(-22.75%)
Market Cap$3775483
P/E Ratio
52W High$19.03
52W Low$0.966
Overview

MetaVia Inc. (MTVA) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

mtva · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for MetaVia Inc. (MTVA) measures how much investors pay for each dollar of the company's trailing earnings. MTVA's current PE ratio of N/A is calculated by dividing its stock price of $1.72 by its TTM earnings per share of -$2.70.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2027 est. EPS $-2.41
Based on 2 analysts
EPS (TTM)
-$2.70
TTM · diluted EPS
PEG Ratio
-0.00
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · MetaVia Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2014 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
MetaVia Inc.
MetaVia Inc.You
MTVA
$4MN/A-$2.70
CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc.
CASI
$2MN/A-$2.56
CollPlant Biotechnologies Ltd.
CollPlant Biotechnologies Ltd.
CLGN
$5MN/A-$0.94
Clearside Biomedical, Inc.
Clearside Biomedical, Inc.
CLSD
$2MN/A-$6.98
Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd.
ENLV
$18M0.03x$27.04
Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc.
KLTO
$20MN/A-$0.32
Lisata Therapeutics, Inc.
Lisata Therapeutics, Inc.
LSTA
$31MN/A-$1.91

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 10 of 12 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-7.35
2024-12-31
FY2024
$-39.13
2023-12-31
FY2023
$-27.05
2022-12-31
FY2022
$-477.57
2021-12-31
FY2021
$-1743.36
2020-12-31
FY2020
$-4831.19
2019-12-31
FY2019
$-10769.08
2018-12-31
FY2018
$-74301.44
2017-12-31
FY2017
$-212834.39
2016-12-31
FY2016
$-104185.71

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for MetaVia Inc. (MTVA) measures how much investors pay for each dollar of the company's trailing earnings. MTVA's current PE ratio of N/A is calculated by dividing its stock price of $1.72 by its TTM earnings per share of -$2.70.

PE Ratio = Stock Price ÷ EPS (TTM)
= $1.72 ÷ -$2.70 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

MTVA pe ratio · 6 questions

MTVA's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.72 and TTM EPS of -$2.70. Data sourced from Financial Modeling Prep via MTVA's SEC 10-K and 10-Q filings.

MTVA PE ratioWhat is MTVA PE ratioCurrent PE ratio of MTVAMTVA PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · MetaVia Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09